Chronic Granulocytic Leukemia cutis Treated with Hydroxyurea

Friedhoff, F.W.; Thelmo, William

doi:10.1159/000237799

Cited by 7 publications

(4 citation statements)

References 6 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2 The most common indications for hydroxyurea therapy are chronic myeloid leukemia 3 and gastrointestinal malignant melanoma. 4 It has also been used in the management of other myeloproliferative disorders, 5 sickle-cell disease, 6 polycythemia vera, 7 psoriasis, 8 and to inhibit viral replication in human immunodeficiency virus disease. 9 While the drug's mode of action on bone marrow elements is well established, its effects on actively proliferating epithelial cells remain less well described.…”

mentioning

confidence: 99%

Hydroxyurea-Induced Leg Ulcers Treated With a Protease-Modulating Matrix

Romanelli¹,

Dini²,

Romanelli³

2007

Arch Dermatol

View full text Add to dashboard Cite

Background: The development of painful leg ulcers in the ankle area is a rare and only partially described complication in patients receiving high-dose, long-term hydroxyurea treatment for myeloproliferative diseases. Several reports have described treatments for chronic wound management with this type of lesion. Observations: We describe 2 patients who were diagnosed as having hydroxyurea-induced leg ulcers that were successfully treated with a freeze-dried sponge containing oxidized regenerated cellulose and bovine purified collagen. This dressing is able to modulate the activity of proteases such as plasmin, neutrophil-derived elastase, and matrix metalloproteinase by physically entrapping them and thus inhibiting their activity. Conclusion: This case demonstrates that topical application of a matrix metalloproteinase modulator can be a successful and safe treatment option for patients with hydroxyurea-induced recalcitrant leg ulcers.

show abstract

mentioning

confidence: 99%

Hydroxyurea-Induced Leg Ulcers Treated With a Protease-Modulating Matrix

Romanelli¹,

Dini²,

Romanelli³

2007

Arch Dermatol

View full text Add to dashboard Cite

show abstract

“…[23][24][25][26][27][28] A lichen planuse like and a dermatomyositis-like reaction specific for HU and termed ''HU dermopathy'' by Daoud et al 29 has been reported with long-term therapy. 11,[30][31][32][33][34][35] The association between HU and multiple aggressive squamous cell carcinomas, Bowen's disease, and multiple actinic keratoses in photoexposed areas after a variable latency period has been increasingly reported in the literature. We report 2 additional patients who experienced the sudden onset of multiple actinic keratoses, Bowen's disease, basal cell carcinomas, and squamous cell carcinomas in sun-exposed areas after long-term HU therapy.…”

mentioning

confidence: 99%

Hydroxyurea-associated squamous dysplasia

Sanchez-Palacios¹,

Guitart²

2004

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…It has been used in patients with hypereosinophilic syndrome unresponsive to corticosteroids 83 . Also, a patient with chronic granulocytic leukaemia cutis who failed to respond to radiotherapy and busulfan experienced healing of skin lesions with hydroxyurea 84 …”

Section: Other Dermatological Uses Of Hydroxyureamentioning

confidence: 99%

Traditional therapies: glucocorticoids, azathioprine, methotrexate, hydroxyurea

Belgi

Friedmann

2002

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

The 'old favourites' used for treatment of inflammatory diseases, and hence, the original immunomodulators, include the glucocorticoids, azathioprine, methotrexate and hydroxyurea. Glucocorticoids are still one of the most effective anti-inflammatory agents because they work on several different intracellular processes and hence, block many components that contribute to inflammatory and immune responses. They bind to intracellular glucocorticoid receptors which transport them into the nucleus. Here the receptor/steroid complex may bind to many genes that interact with transcription factors including NFkappaB and AP-1, to inhibit their activation, thereby preventing activation of many genes encoding immune effector and pro-inflammatory cytokines. Also, protein kinases involved in intracellular signalling, are directly activated resulting in phosphorylation of various targets of which Annexin (AXA)-1 is critical in inhibiting biosynthesis of both purines and DNA. This results in reduced proliferation of B and T lymphocytes, reduced immune effector mechanisms and reduced recruitment of mononuclear cells including monocytes into sites of immune inflammation. Methotrexate also blocks DNA synthesis and hence cellular proliferation but also induces release of adenosine. This inhibits chemotaxis of polymorph neutrophils and release of critical cytokines such as TNF-alpha and Interleukins 6 and 8. Hydroxyurea also inhibits DNA synthesis with inhibitory effects on proliferation of lymphocytes and possibly kerationcytes. Even though many new agents with much greater selectivity are coming through into clinical use, this group of old agents still have an absolutely central position in the therapeutic armamentarium. Their value lies in the fact that they are not 'clean' drugs with narrow effects but they inhibit a wide range of mechanisms involved in immune and inflammatory processes.

show abstract

Chronic Granulocytic Leukemia cutis Treated with Hydroxyurea

Cited by 7 publications

References 6 publications

Hydroxyurea-Induced Leg Ulcers Treated With a Protease-Modulating Matrix

Hydroxyurea-Induced Leg Ulcers Treated With a Protease-Modulating Matrix

Hydroxyurea-associated squamous dysplasia

Traditional therapies: glucocorticoids, azathioprine, methotrexate, hydroxyurea

Contact Info

Product

Resources

About